DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a ...

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Novo Nordisk (NYSE: NVO) is working with Durham-based IMMvention Therapeutix to jointly develop oral therapies for the disease and other chronic conditions. The companies did not disclose the ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a ...

IMMvention partners with Novo Nordisk to co-develop oral therapies for sickle cell disease using BACH1 inhibitors. Novo Nordisk to handle further development, regulatory, and commercialization ...

It is being spearheaded by Anil Goyal, CEO of IMMvention Therapeutics and Joe Ruiz, president of Enzerna Biosciences. Paredes, who is the captain of her debate team, the Red Cross Club ...